All Stories

  1. From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA—A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression
  2. First steps in the treatment of advanced Parkinson’s disease with foslevodopa/foscarbidopa continuous subcutaneous infusion
  3. Prevalence and Associations of Poor Sleep in Patients with Relapsing-Remitting Multiple Sclerosis on Disease-Modifying Therapy
  4. Differences in acute ischemic stroke treatment: A cross-sectional study from international Registry of Stroke Care Quality (RES-Q)
  5. Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies
  6. Eficacia en la vida real del fingolimod en pacientes con esclerosis múltiple en Bulgaria
  7. Platelets’ Nanomechanics and Morphology in Neurodegenerative Pathologies
  8. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
  9. Efficacy and safety of adjunctive cenobamate: Post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications
  10. Morphometry and Stiffness of Red Blood Cells—Signatures of Neurodegenerative Diseases and Aging
  11. Red Blood Cells’ Thermodynamic Behavior in Neurodegenerative Pathologies and Aging
  12. The development and use of the European academy of neurology guideline on palliative care in advanced progressive multiple sclerosis
  13. Translation, adaptation and validation of the Bulgarian version of the King’s Parkinson’s Disease Pain Scale
  14. Clinical Correlation between Hormonal Status and Autonomic Nervous System Function in Patients with Fibromyalgia
  15. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description
  16. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity
  17. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis
  18. Neurophysiological Findings in Chronic Pain Syndromes
  19. Repetitive Transcranial Magnetic Stimulation over Two Target Areas, Sham Stimulation and Topiramate in the Treatment of Chronic Migraine
  20. Pitfals in recognition and management of trigeminal neuralgia
  21. Palliative care in multiple sclerosis: European guideline
  22. EAN guideline on palliative care of people with severe, progressive multiple sclerosis
  23. Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures – Authors' reply
  24. Update on the Management of Parkinson’s Disease for General Neurologists
  25. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
  26. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
  27. Novel Approach for Objective Quantification of Locomotor Disturbaces in Low Back Pain
  28. Neutralizing Antibodies against Interferon‑beta in Bulgarian Adolescent Multiple Sclerosis Patients
  29. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis
  30. Do Binding Antibodies Predict Neutralizing Antibody Development in Multiple Sclerosis Patients?
  31. Starvation, Strachan's syndrome, and postgastroplasty syndrome
  32. Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes
  33. F-Wave in the Upper Extremities of Patients with Primary Torsion Dystonia
  34. Serum levels of EBVNA-IgG and EBVCA-IgG in patients with multiple sclerosis
  35. Trigeminal Nerve Reflexes in Chronic Pain Syndromes
  36. Back pain
  37. Back pain
  38. Trigeminal Neuralgia
  39. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
  40. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
  41. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
  42. Diagnostic value of combinations of symptoms of migraine and tension-type headache included in the diagnostic criteria for children and adolescents in the international classification of headache disorders 2nd edition
  43. Chromosomal radiosensitivity in patients with multiple sclerosis
  44. How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
  45. Evaluation of diagnostic and prognostic value of clinical characteristics of Migraine and Tension type headache included in the diagnostic criteria for children and adolescents in International Classification of Headache Disorders - second edition
  46. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
  47. Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
  48. Prevalence of Dementia and Mild Cognitive Impairment in a Bulgarian Urban Population
  49. A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study
  50. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
  51. Implementation and impact of headache guidelines
  52. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
  53. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis
  54. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
  55. Transient Mutism and Pathologic Laughter in the Course of Cerebellitis
  56. Mechanisms of tizanidine action on spasticity
  57. Mechanisms of baclofen action on spasticity
  58. Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients wi...
  59. Determination of plasma aminothiols by high performance liquid chromatography after precolumn derivatization with N-(2-acridonyl)maleimide
  60. P013 Neurophysiological study on facial F-waves in patients with primary headache and with Parkinson's disease
  61. P234 Monitoring of drug efficacy on different types of tremor in Parkinson's disease
  62. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
  63. Therapeutic Use of Nicergoline
  64. S.01.02 Tension-type headache
  65. 1.184 Cognitive impairments in patients with early Parkinson's disease
  66. Abnormal Modulatory Influence of Diffuse Noxious Inhibitory Controls in Migraine and Chronic Tension-Type Headache Patients
  67. The epidemiology of multiple sclerosis in Europe
  68. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  69. Acute reversible parkinsonism in Epstein–Bbarr virus–related encephalitis lethargica‐like illness
  70. Pain and tension-type headache: a review of the possible pathophysiological mechanisms
  71. Lower limb SSEP changes in stroke—predictive values regarding functional recovery
  72. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine.
  73. Trigemino-Cervical Reflex in Patients with Headache
  74. Clinical and electromyographic assessment of essential tremor treatment
  75. Antiphospholipid syndrome and dystonia-parkinsonism
  76. Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine
  77. Antiphospholipid syndrome and dystonia-parkinsonism
  78. Electromyographic differentiation of tremors
  79. A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor
  80. Clinical and electromyographic examinations of patients with tremor after chronic occupational lead exposure
  81. Antiphospholipid syndrome and dystonia–parkinsonism. A case report
  82. Prevalence of Parkinson’s Disease in Bulgaria
  83. Effects of Sleep on Spinal Nociceptive Reflexes in Humans
  84. Clinical and electromyographic examinations of Parkinsonian tremor
  85. Asymmetrical reduction of the nociceptive flexion reflex threshold in cluster headache
  86. Asymmetrical Reduction of the Nociceptive Flexion Reflex Threshold in Cluster Headache
  87. Acupuncture for episodic tension-type headache: a multicentre randomized controlled trial
  88. Effects of hypnosis on diffuse noxious inhibitory controls
  89. Clinical and electromyographic characteristics of tremor in patients with depression
  90. Clinical and Electromyographic Examinations of Patients with Essential Tremor
  91. Prevalence of Parkinson’s Disease in Bulgarian Gypsies
  92. Neurophysiological approach to the study of cluster headache
  93. Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients
  94. Prevalence of Multiple Sclerosis in Gypsies and Bulgarians
  95. Contralateral hemi-parkinsonism and atypical tremor after stroke (a case report)
  96. Parkinsonian Syndrome as a Neurological Manifestation of Behcet's Disease
  97. 1-02-06 Differential diagnosis of amyotrophic lateral sclerosis and similar syndromes
  98. Prevalence of Multiple Sclerosis in Bulgaria
  99. P169 Differential diagnosis of limb girdle syndromes
  100. Writer’s Cramp and Tremor Due to Brain Tumor
  101. Vestibular and auditory influences on segmental motoneuron excitability — a comparative study
  102. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy and Skin Changes (Poems) Syndrome
  103. A comparative study of methods for estimation of presynaptic inhibition
  104. A Comparison of Methods to Assess the Excitability of Lower Motoneurones